Evaluation of Cardiovascular Risk Factors after Hepatitis C Virus Eradication with Direct-Acting Antivirals in a Cohort of Treatment-Naïve Patients without History of Cardiovascular Disease.

Diego Casas DezaAna Martínez-SapiñaSilvia EspinaBeatriz Garcia-RodriguezEva M Fernandez-BonillaAlejandro Sanz-París Yolanda Gonzalez-Irazabal Vanesa Bernal-Monterde Jose Miguel Arbones-Mainar

Published in: Journal of clinical medicine (2022)

DAA treatments returned plasma lipids to the normal range without increasing either the occurrence of cardiovascular events or the consumption of lipid-lowering medication beyond what is normal in a sex- and age-matched population.

Keyphrases

cardiovascular events
cardiovascular risk factors
cardiovascular disease
hepatitis c virus
end stage renal disease
coronary artery disease
newly diagnosed
chronic kidney disease
type diabetes
metabolic syndrome
prognostic factors
emergency department
combination therapy
adverse drug
helicobacter pylori